Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Chronic renal allograft dysfunction: a role for mycophenolate mofetil?

Pascual M, Williams WW, Cosimi AB, Delmonico FL, Farrell ML, Tolkoff-Rubin N.

Transplantation. 2000 Apr 27;69(8):1749-50. No abstract available.

PMID:
10836397
2.

Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction.

Islam MS, Francos GC, Dunn SR, Burke JF Jr.

Transplant Proc. 1998 Aug;30(5):2230-1. No abstract available.

PMID:
9723452
3.

Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction.

Senn B, Rochat P, Schwarzkopf AK, Weinreich T, Binswanger U.

Transplant Proc. 1998 Dec;30(8):4075-6. No abstract available.

PMID:
9865301
4.

A single center experience with mycophenolate mofetil in the prevention of renal allograft rejection.

Behrend M, Lück R, Köthe P, Pichlmayr R.

Transplant Proc. 1996 Dec;28(6):3110-1. No abstract available.

PMID:
8962205
5.
6.

Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-center experience in 40 patients.

Kliem V, Boeck A, Eisenberger U, Petersen R, Radermacher J, Hiss M, Pethig M, Koch KM, Nashan B, Brunkhorst R.

Transplant Proc. 1999 Feb-Mar;31(1-2):1312-3. No abstract available.

PMID:
10083586
7.

Treatment of chronic allograft nephropathy with mycophenolate mofetil after kidney transplantation: a Spanish multicenter study.

González Molina M, Serón D, García del Moral R, Carrera M, Sola E, Gómez Ullate P, Capdevila L, Gentil MA; Spanish Mycophenolate Mofetil and Chronic Graft Nephropathy Study Group.

Transplant Proc. 2002 Feb;34(1):335-7. No abstract available.

PMID:
11959313
8.

A randomized trial of mycophenolate mofetil versus azathioprine as calcineurin inhibitor sparing agents in the treatment of chronic allograft nephropathy.

Metcalfe MS, Jain S, Waller JR, Saunders RN, Bicknell GR, Nicholson ML.

Transplant Proc. 2002 Aug;34(5):1812-4. No abstract available.

PMID:
12176587
9.

Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation.

Crespo JF, Górriz JL, Sancho A, Avila A, Alcoy E, Pallardó LM.

Transplant Proc. 1999 Sep;31(6):2261-2. No abstract available.

PMID:
10500568
10.

Mycophenolate mofetil in living donor renal allograft recipients.

Park K, Moon JI, Kim SI, Kim YS.

Transplant Proc. 1999 Feb-Mar;31(1-2):1133. No abstract available.

PMID:
10083506
11.

Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation.

Wüthrich RP, Cicvara S, Ambühl PM, Binswanger U.

Nephrol Dial Transplant. 2000 Aug;15(8):1228-31.

PMID:
10910450
12.

Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors.

Theodorakis J, Schneeberger H, Illner WD, Stangl M, Zanker B, Land W.

Transplant Proc. 2000 Feb;32(1A Suppl):9S-11S. No abstract available.

PMID:
10686311
13.

Reduction in the incidence of early rejection in cadaveric renal allograft recipients treated with ATGAM induction and sequential mycophenolate mofetil.

Florence LS, Howard DR, Chapman PH, Lieberman J, Perkinson DT, Marks WH.

Transplant Proc. 1997 Feb-Mar;29(1-2):313-4. No abstract available.

PMID:
9123016
14.

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.

Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C.

Transplantation. 1997 Jan 15;63(1):39-47. Erratum in: Transplantation 1997 Feb 27;63(4):618.

PMID:
9000658
15.

Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients.

Fritsche L, Sperschneider H, Budde K, Giessing M, Morgera S, Schröder K, Stein G, Neumayer HH.

Transplant Proc. 1998 Jun;30(4):1190-1. No abstract available.

PMID:
9636481
16.

Kaposi's sarcoma after renal transplantation--disappearance after reduction of immunosuppression and reappearance 7 years later after start of mycophenolate mofetil treatment.

Gómez E, Aguado S, Rodríguez M, Alvarez-Grande J.

Nephrol Dial Transplant. 1998 Dec;13(12):3279-80. No abstract available.

PMID:
9870518
17.

Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.

Park K, Kim SI, Moon JI, Kim YS, Kim MS.

Transplant Proc. 1998 Nov;30(7):3575. No abstract available.

PMID:
9838565
18.

Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function.

Fritsche L, Sperschneider H, Budde K, Giessing M, Türk H, Böhler T, Schröder K, Stein G, Neumayer HH.

Transplant Proc. 1998 Aug;30(5):2229. No abstract available.

PMID:
9723451
19.

Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.

Esmeraldo RM, Donadi MO, Oliveira ML, Ponte CN, Pinheiro PM.

Transplant Proc. 1999 Nov;31(7):3007-8. No abstract available.

PMID:
10578367
20.

Mycophenolate mofetil as an effective alternative to cyclosporin in post-transplant haemolytic uraemic syndrome.

Agarwal DK, Gulati S, Mehta A, Kumar A, Sharma RK, Mehta B, Gupta A, Gupta RK.

Nephrol Dial Transplant. 2000 Dec;15(12):2064-5. No abstract available.

PMID:
11096161

Supplemental Content

Support Center